Oncolytics Biotech Inc. (TSE:ONC - Get Free Report) Senior Officer Andrew P. Aromando bought 25,500 shares of the company's stock in a transaction that occurred on Tuesday, July 15th. The stock was purchased at an average price of C$1.62 per share, for a total transaction of C$41,425.92.
Oncolytics Biotech Stock Performance
TSE:ONC traded down C$0.05 during trading hours on Friday, reaching C$1.73. The company had a trading volume of 245,934 shares, compared to its average volume of 147,357. The company has a debt-to-equity ratio of 11.75, a current ratio of 2.99 and a quick ratio of 8.86. Oncolytics Biotech Inc. has a 1-year low of C$0.44 and a 1-year high of C$2.08. The business's 50 day moving average price is C$0.90 and its 200-day moving average price is C$0.95. The firm has a market cap of C$133.34 million, a PE ratio of -4.82 and a beta of 1.35.
Analyst Ratings Changes
Separately, Jones Trading lowered shares of Oncolytics Biotech from a "strong-buy" rating to a "hold" rating in a report on Friday, May 16th.
Get Our Latest Analysis on Oncolytics Biotech
Oncolytics Biotech Company Profile
(
Get Free Report)
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
Further Reading
Before you consider Oncolytics Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oncolytics Biotech wasn't on the list.
While Oncolytics Biotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
